121 related articles for article (PubMed ID: 30655848)
1. Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy.
Kanke Y; Saito M; Abe N; Saito K; Goto A; Ohtake T; Murakami Y; Kono K
Oncol Lett; 2019 Jan; 17(1):921-926. PubMed ID: 30655848
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer.
Saito M; Goto A; Abe N; Saito K; Maeda D; Ohtake T; Murakami Y; Takenoshita S
Oncol Lett; 2018 Feb; 15(2):2401-2406. PubMed ID: 29434950
[TBL] [Abstract][Full Text] [Related]
3. Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma.
Nagata M; Sakurai-Yageta M; Yamada D; Goto A; Ito A; Fukuhara H; Kume H; Morikawa T; Fukayama M; Homma Y; Murakami Y
Int J Cancer; 2012 Mar; 130(6):1329-37. PubMed ID: 21544807
[TBL] [Abstract][Full Text] [Related]
4. Synaptic adhesion molecules in Cadm family at the neuromuscular junction.
Tanabe Y; Fujita E; Hayashi YK; Zhu X; Lubbert H; Mezaki Y; Senoo H; Momoi T
Cell Biol Int; 2013 Jul; 37(7):731-6. PubMed ID: 23505055
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Analysis of Interaction Between CADM1 and Its Binding Cell-Surface Proteins Using Surface Plasmon Resonance Imaging.
Ito T; Kasai Y; Kumagai Y; Suzuki D; Ochiai-Noguchi M; Irikura D; Miyake S; Murakami Y
Front Cell Dev Biol; 2018; 6():86. PubMed ID: 30131958
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer.
Takahashi Y; Iwai M; Kawai T; Arakawa A; Ito T; Sakurai-Yageta M; Ito A; Goto A; Saito M; Kasumi F; Murakami Y
Breast Cancer; 2012 Jul; 19(3):242-52. PubMed ID: 21526423
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
8. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
9. Expression of mTOR Signaling Pathway Molecules in Triple-Negative Breast Cancer.
Ito K; Ogata H; Honma N; Shibuya K; Mikami T
Pathobiology; 2019; 86(5-6):315-321. PubMed ID: 31707383
[TBL] [Abstract][Full Text] [Related]
10. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
[TBL] [Abstract][Full Text] [Related]
11. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
14. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
15. Diaphanous-related formin-3 overexpression inhibits the migration and invasion of triple-negative breast cancer by inhibiting RhoA-GTP expression.
Jiang J
Biomed Pharmacother; 2017 Oct; 94():439-445. PubMed ID: 28779705
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Lox in triple-negative breast cancer.
Leo C; Cotic C; Pomp V; Fink D; Varga Z
Ann Diagn Pathol; 2018 Jun; 34():98-102. PubMed ID: 29661738
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho RK; Yam C; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Hong D; Kurzrock R; Hortobagyi GN; Janku F; Moulder SL
Oncologist; 2018 Nov; 23(11):1300-1309. PubMed ID: 30139837
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico.
Uscanga-Perales GI; Santuario-Facio SK; Sanchez-Dominguez CN; Cardona-Huerta S; Muñoz-Maldonado GE; Ruiz-Flores P; Barcenas-Walls JR; Osuna-Rosales LE; Rojas-Martinez A; Gonzalez-Guerrero JF; Valero-Gomez J; Gomez-Macias GS; Barbosa-Quintana A; Barboza-Quintana O; Garza-Guajardo R; Ortiz-Lopez R
Oncol Lett; 2019 Mar; 17(3):3581-3588. PubMed ID: 30867801
[TBL] [Abstract][Full Text] [Related]
20. Phemindole, a Synthetic Di-indole Derivative Maneuvers the Store Operated Calcium Entry (SOCE) to Induce Potent Anti-Carcinogenic Activity in Human Triple Negative Breast Cancer Cells.
Chakraborty S; Ghosh S; Banerjee B; Santra A; Adhikary A; Misra AK; Sen PC
Front Pharmacol; 2016; 7():114. PubMed ID: 27199756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
